Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major ...

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage ...

The companies have not published the trial data but said in a news release that the experimental treatment extended the time ...

Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...

A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

CHICAGO, Aug 19 (Reuters) - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

A personalized mRNA cancer vaccine, added to an existing treatment, slowed the return of melanoma and its spread to other ...

Pharmaceutical giants Moderna and Merck say an experimental vaccine treatment for melanoma has shown signs of preventing the ...

Moderna and Merck said their personalized cancer treatment showed positive results in their first-ever late-stage trial. Here ...